Most children with PWS nowadays receive growth hormone (GH) treatment, which counteracts the clinical course of obesity and improves the metabolic profile, leading to better lipid levels, higher adiponectin levels, and lower systolic blood pressure [6, 7]. This evidence concerns the gene GH1 and obesity due to melanocortin 4 receptor deficiency.